Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC

BACKGROUND: Advanced non-small cell lung cancer patients receiving TG4010, a therapeutic viral vaccine encoding human Mucin 1 and interleukin-2 in addition to standard chemotherapy, displayed longer overall survival in comparison to that of patients treated with standard chemotherapy alone. Our stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Tosch, Caroline, Bastien, Bérangère, Barraud, Luc, Grellier, Benoit, Nourtier, Virginie, Gantzer, Murielle, Limacher, Jean Marc, Quemeneur, Eric, Bendjama, Kaïdre, Préville, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604422/
https://www.ncbi.nlm.nih.gov/pubmed/28923084
http://dx.doi.org/10.1186/s40425-017-0274-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604422/
https://www.ncbi.nlm.nih.gov/pubmed/28923084
http://dx.doi.org/10.1186/s40425-017-0274-x

Ejemplares similares